O	0	8	Efficacy
O	9	12	and
O	13	19	safety
O	20	22	of
B-intervention	23	38	lipegfilgrastim
O	39	45	versus
B-control	46	59	pegfilgrastim
O	59	60	:
O	61	62	a
O	63	73	randomized
O	73	74	,
O	75	86	multicenter
O	86	87	,
O	88	94	active
O	94	95	-
O	95	102	control
O	103	108	phase
O	109	110	3
O	111	116	trial
O	117	119	in
O	120	128	patients
O	129	133	with
O	134	140	breast
O	141	147	cancer
O	148	157	receiving
O	158	169	doxorubicin
O	169	170	/
O	170	179	docetaxel
O	180	192	chemotherapy
O	192	193	.

O	194	209	Lipegfilgrastim
O	210	212	is
O	213	214	a
O	215	220	novel
O	221	226	glyco
O	226	227	-
O	227	236	pegylated
O	237	248	granulocyte
O	248	249	-
O	249	255	colony
O	256	267	stimulating
O	268	274	factor
O	275	277	in
O	278	289	development
O	290	293	for
O	294	305	neutropenia
O	306	317	prophylaxis
O	318	320	in
O	321	327	cancer
O	328	336	patients
O	337	346	receiving
O	347	359	chemotherapy
O	359	360	.

O	361	365	This
O	366	371	phase
O	372	375	III
O	375	376	,
O	377	383	double
O	383	384	-
O	384	389	blind
O	389	390	,
O	391	401	randomized
O	401	402	,
O	403	409	active
O	409	410	-
O	410	420	controlled
O	420	421	,
O	422	436	noninferiority
O	437	442	trial
O	443	451	compared
O	452	455	the
O	456	464	efficacy
O	465	468	and
O	469	475	safety
O	476	478	of
O	479	494	lipegfilgrastim
O	495	501	versus
O	502	515	pegfilgrastim
O	516	518	in
O	519	531	chemotherapy
O	531	532	-
O	532	534	na
O	534	535	ï
O	535	537	ve
O	538	544	breast
O	545	551	cancer
O	552	560	patients
O	561	570	receiving
O	571	582	doxorubicin
O	582	583	/
O	583	592	docetaxel
O	593	605	chemotherapy
O	605	606	.

B-eligibility	607	615	Patients
I-eligibility	616	620	with
I-eligibility	621	625	high
I-eligibility	625	626	-
I-eligibility	626	630	risk
I-eligibility	631	636	stage
I-eligibility	637	639	II
I-eligibility	639	640	,
I-eligibility	641	644	III
I-eligibility	644	645	,
I-eligibility	646	648	or
I-eligibility	649	651	IV
I-eligibility	652	658	breast
I-eligibility	659	665	cancer
I-eligibility	666	669	and
I-eligibility	670	672	an
I-eligibility	673	681	absolute
I-eligibility	682	692	neutrophil
I-eligibility	693	698	count
I-eligibility	699	700	≥
I-eligibility	700	701	1
I-eligibility	701	702	.
I-eligibility	702	703	5
I-eligibility	704	705	×
I-eligibility	706	709	109
I-eligibility	710	715	cells
I-eligibility	715	716	/
I-eligibility	716	717	L
O	718	722	were
O	723	733	randomized
O	734	736	to
O	737	738	a
O	739	745	single
O	746	747	6
O	747	748	-
O	748	750	mg
O	751	763	subcutaneous
O	764	773	injection
O	774	776	of
O	777	792	lipegfilgrastim
O	793	794	(
O	794	795	n
O	796	797	=
B-intervention-participants	798	801	101
O	801	802	)
O	803	805	or
O	806	819	pegfilgrastim
O	820	821	(
O	821	822	n
O	823	824	=
B-control-participants	825	828	101
O	828	829	)
O	830	832	on
O	833	836	day
O	837	838	2
O	839	841	of
O	842	846	each
O	847	849	21
O	849	850	-
O	850	853	day
O	854	866	chemotherapy
O	867	872	cycle
O	873	874	(
O	874	875	4
O	876	882	cycles
O	883	890	maximum
O	890	891	)
O	891	892	.

O	893	896	The
O	897	904	primary
O	905	913	efficacy
O	914	922	endpoint
O	923	926	was
O	927	930	the
B-outcome-Measure	931	939	duration
I-outcome-Measure	940	942	of
I-outcome-Measure	943	949	severe
I-outcome-Measure	950	961	neutropenia
I-outcome-Measure	962	968	during
I-outcome-Measure	969	974	cycle
I-outcome-Measure	975	976	1
O	976	977	.

O	978	983	Cycle
O	984	985	1
O	985	986	:
O	987	990	The
B-outcome	991	995	mean
I-outcome	996	1004	duration
I-outcome	1005	1007	of
I-outcome	1008	1014	severe
I-outcome	1015	1026	neutropenia
O	1027	1030	for
O	1031	1034	the
O	1035	1050	lipegfilgrastim
O	1051	1054	and
O	1055	1068	pegfilgrastim
O	1069	1075	groups
O	1076	1079	was
B-iv-cont-mean	1080	1081	0
I-iv-cont-mean	1081	1082	.
I-iv-cont-mean	1082	1083	7
O	1084	1087	and
B-cv-cont-mean	1088	1089	0
I-cv-cont-mean	1089	1090	.
I-cv-cont-mean	1090	1091	8
I-cv-cont-mean	1092	1096	days
O	1096	1097	,
O	1098	1110	respectively
O	1111	1112	(
O	1112	1113	λ
O	1114	1115	=
O	1116	1117	-
O	1117	1118	0
O	1118	1119	.
O	1119	1122	218
O	1123	1124	[
O	1124	1126	95
O	1126	1127	%
O	1128	1138	confidence
O	1139	1147	interval
O	1147	1148	:
O	1149	1150	-
O	1150	1151	0
O	1151	1152	.
O	1152	1155	498
O	1155	1156	%
O	1156	1157	,
O	1158	1159	0
O	1159	1160	.
O	1160	1163	062
O	1163	1164	%
O	1164	1165	]
O	1165	1166	,
O	1167	1168	p
O	1169	1170	=
O	1171	1172	0
O	1172	1173	.
O	1173	1176	126
O	1176	1177	)
O	1177	1178	,
O	1179	1182	and
B-outcome	1183	1185	no
I-outcome	1186	1192	severe
I-outcome	1193	1204	neutropenia
O	1205	1208	was
O	1209	1217	observed
O	1218	1220	in
B-iv-bin-percent	1221	1223	56
I-iv-bin-percent	1223	1224	%
O	1225	1228	and
B-cv-bin-percent	1229	1231	49
I-cv-bin-percent	1231	1232	%
O	1233	1235	of
O	1236	1244	patients
O	1245	1247	in
O	1248	1251	the
O	1252	1267	lipegfilgrastim
O	1268	1271	and
O	1272	1285	pegfilgrastim
O	1286	1292	groups
O	1292	1293	,
O	1294	1306	respectively
O	1306	1307	.

O	1308	1311	All
O	1312	1318	cycles
O	1318	1319	:
O	1320	1322	In
O	1323	1326	the
O	1327	1335	efficacy
O	1336	1346	population
O	1346	1347	,
B-outcome	1348	1355	febrile
I-outcome	1356	1367	neutropenia
O	1368	1376	occurred
O	1377	1379	in
B-cv-bin-abs	1380	1385	three
O	1386	1399	pegfilgrastim
O	1399	1400	-
O	1400	1407	treated
O	1408	1416	patients
O	1417	1418	(
O	1418	1421	all
O	1422	1424	in
O	1425	1430	cycle
O	1431	1432	1
O	1432	1433	)
O	1434	1437	and
B-iv-bin-abs	1438	1442	zero
O	1443	1458	lipegfilgrastim
O	1458	1459	-
O	1459	1466	treated
O	1467	1475	patients
O	1475	1476	.

B-outcome	1477	1481	Drug
I-outcome	1481	1482	-
I-outcome	1482	1489	related
I-outcome	1490	1497	adverse
I-outcome	1498	1504	events
O	1505	1507	in
O	1508	1511	the
O	1512	1518	safety
O	1519	1529	population
O	1530	1534	were
O	1535	1543	reported
O	1544	1546	in
B-iv-bin-percent	1547	1549	28
I-iv-bin-percent	1549	1550	%
O	1551	1554	and
B-cv-bin-percent	1555	1557	26
I-cv-bin-percent	1557	1558	%
O	1559	1561	of
O	1562	1570	patients
O	1571	1573	in
O	1574	1577	the
O	1578	1593	lipegfilgrastim
O	1594	1597	and
O	1598	1611	pegfilgrastim
O	1612	1618	groups
O	1618	1619	,
O	1620	1632	respectively
O	1632	1633	.

O	1634	1638	This
O	1639	1644	study
O	1645	1657	demonstrates
O	1658	1662	that
O	1663	1678	lipegfilgrastim
O	1679	1680	6
O	1681	1683	mg
O	1684	1686	is
O	1687	1689	as
O	1690	1699	effective
O	1700	1702	as
O	1703	1716	pegfilgrastim
O	1717	1719	in
O	1720	1728	reducing
O	1729	1740	neutropenia
O	1741	1743	in
O	1744	1752	patients
O	1753	1757	with
O	1758	1764	breast
O	1765	1771	cancer
O	1772	1781	receiving
O	1782	1798	myelosuppressive
O	1799	1811	chemotherapy
O	1811	1812	.

O	1813	1818	Eudra
O	1819	1837	EEACTA200901599910
O	1837	1838	.
